UCL Ventures’ spinout creation achievements awarded at One Nucleus

Members of UCL Ventures’s Biopharm team joined life science innovators at last night’s event in London to celebrate their incredible achievements. The One Nucleus Award categories are structured to reflect the breadth of R&D, investment, service provision and enabling support across the stakeholders.

UCL Ventures won the Best Performing New Company Creator of the Year award, a category that assesses technology transfer offices, accelerators/incubators, start-up funders and advisers creating and supporting new ventures.

The category assesses criteria including new company creation activity, internal investment, external investment secured, business support provided, support of founder diversity and promotion of entrepreneurship in life sciences.

Mark Fisher, Associate Director of BioPharm, UCL Ventures, said: “UCL Ventures is honoured to be acknowledged for our role in supporting and advancing UCL’s dynamic spin-out ecosystem. The award reflects UCL Ventures’s dedication to fostering innovation, translating groundbreaking research into impactful ventures, and driving positive change across industries and communities.  

“It also reflects the depth of experience provided by the whole team at UCL Ventures and underlines the importance of direct access to venture-growing funds – such as our own Proof of Concept fund, and external venture capital – that accelerate company growth.”

UCL Ventures’s Dr Mark Fisher, Associate Director of BioPharm and Dr Caitriona O’Rourke, Senior Business Manager, with the award.